IL1B and familial Mediterranean fever: Inflammation in patients with FMF is effectively controlled with colchicine or with treatments targeting interleukin (IL)-1β, which include anakinra (a recombinant human IL-1 receptor antagonist), canakinumab (a human IgG1 monoclonal antibody directed against IL-1β) [9], and rilonacept (a fully human dimeric fusion protein; nonregistered indication) [10].